Hall SarahRose, Samani Stephanie, Churillo Amelia, Freeburg Lisa, Cohen Oren, Devarakonda Kavya, Khan Samira, Barringhaus Kurt G, Shah Neomi, Spinale Francis G
Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC.
Division of Pulmonary, Sleep, and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Med Res Arch. 2024 Jan;12(1). doi: 10.18103/mra.v12i1.4975.
Obstructive sleep apnea (OSA) has been linked to cytokine-mediated chronic inflammatory states. Continuous positive airway pressure (CPAP) is an established therapy for OSA, but its effects on inflammation remain unclear. A recent study from our group identified soluble cytokine receptors altered in OSA patients and modified by CPAP adherence. However, the upstream regulatory pathways responsible for these shifts in proinflammatory cascades with OSA and CPAP therapy remained unknown. Accordingly, this study mapped OSA and CPAP-modulated soluble cytokine receptors to specific microRNAs and then tested the hypothesis that OSA and CPAP adherence shift cytokine-related microRNA expression profiles.
Plasma samples were collected from patients with OSA (n=50) at baseline and approximately 90 days after CPAP initiation and compared to referent control subjects (n=10). Patients with OSA were further divided into cohorts defined by adherence vs nonadherence to CPAP therapy. The microRNAs that mapped to soluble cytokine receptors of interest were subjected to quantitative polymerase chain reaction.
At baseline, increased hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-195-5p, hsa-miR-424-5p, hsa-miR-223-3p, and hsa-miR-223-5p were observed in patients with OSA compared to controls (p<0.05). In CPAP adherent patients (n=22), hsa-miR233-3p and hsa-miR233-5p decreased at follow-up (p<0.05) whereas there was no change in miR levels from baseline in non-adherent CPAP patients (n=28). The miRs hsa-miR233-3p and hsa-miR233-5p mapped to both proinflammatory and innate immunity activation; the inflammasome.
A specific set of microRNAs, including hsa-miR233-3p and hsa-miR233-5p, may serve as a marker of inflammatory responses in patients with OSA, and be used to assess attenuation of inflammasome activation by CPAP.
阻塞性睡眠呼吸暂停(OSA)与细胞因子介导的慢性炎症状态有关。持续气道正压通气(CPAP)是治疗OSA的一种既定疗法,但其对炎症的影响仍不清楚。我们团队最近的一项研究发现,OSA患者体内可溶性细胞因子受体发生改变,并受到CPAP依从性的影响。然而,OSA和CPAP治疗导致促炎级联反应发生这些变化的上游调节途径仍然未知。因此,本研究将OSA和CPAP调节的可溶性细胞因子受体与特定的微小RNA进行映射,然后检验OSA和CPAP依从性会改变细胞因子相关微小RNA表达谱这一假设。
在基线时以及CPAP治疗开始后约90天,从OSA患者(n = 50)中采集血浆样本,并与对照受试者(n = 10)进行比较。OSA患者进一步分为依从CPAP治疗组和不依从CPAP治疗组。对与感兴趣的可溶性细胞因子受体相关的微小RNA进行定量聚合酶链反应。
与对照组相比,在基线时,OSA患者中hsa-miR-15a-5p、hsa-miR-15b-5p、hsa-miR-16-5p、hsa-miR-195-5p、hsa-miR-424-5p、hsa-miR-223-3p和hsa-miR-223-5p水平升高(p<0.05)。在依从CPAP治疗的患者(n = 22)中,hsa-miR233-3p和hsa-miR233-5p在随访时下降(p<0.05),而在不依从CPAP治疗的患者(n = 28)中,miR水平与基线相比没有变化。hsa-miR233-3p和hsa-miR233-5p这两种微小RNA与促炎和先天免疫激活(炎性小体)相关。
一组特定的微小RNA,包括hsa-miR233-3p和hsa-miR233-5p,可能作为OSA患者炎症反应的标志物,并用于评估CPAP对炎性小体激活的减弱作用。